EGFR and non-small cell lung carcinoma: Exon 14 skipping mutation (EM) of MET has been demonstrated as a discrete NSCLC hallmark, prevailing discretely from the EGFR, ALK and c-ROS mutations besides being associated with a poor prognosis.